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Background: The Li-Fraumeni syndrome (LFS), an inherited rare cancer predisposition syndrome characterized by a
variety of early-onset tumors, is caused by different highly penetrant germline mutations in the TP53 gene; each
separate mutation has dissimilar functional and phenotypic effects, which partially clarifies the reported
heterogeneity between LFS families. Increases in copy number variation (CNV) have been reported in TP53 mutated
individuals, and are also postulated to contribute to LFS phenotypic variability. The Brazilian p.R337H TP53 mutation
has particular functional and regulatory properties that differ from most other common LFS TP53 mutations, by
conferring a strikingly milder phenotype.
Methods: We compared the CNV profiles of controls, and LFS individuals carrying either p.R337H or DNA binding
domain (DBD) TP53 mutations by high resolution array-CGH.
Results: Although we did not find any significant difference in the frequency of CNVs between LFS patients and
controls, our data indicated an increased proportion of rare CNVs per genome in patients carrying DBD mutations
compared to both controls (p=0.0002***) and p.R337H (0.0156*) mutants.
Conclusions: The larger accumulation of rare CNVs in DBD mutants may contribute to the reported anticipation
and severity of the syndrome; likewise the fact that p.R337H individuals do not present the same magnitude of rare
CNV accumulation may also explain the maintenance of this mutation at relatively high frequency in some
populations.
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Li-Fraumeni syndrome (LFS; OMIM #151623) is an
autosomal dominant highly penetrant cancer predispos-
ition syndrome characterized by a variety of early onset
tumors [1,2]. LFS arises from germline mutations in the
TP53 gene, which codes for a transcription factor impli-
cated in cell proliferation, apoptosis, and genomic stabil-
ity [3,4]. Although decreases in the age of cancer onset
and increases in cancer incidence over successive gen-
erations have been documented in LFS [5,6], the mo-
lecular basis of this anticipation is still a matter of
debate.
Most mutations in the TP53 gene affect the DNA
binding domain (DBD) and result in missense substitu-
tions giving rise to altered proteins [7] that have a* Correspondence: carlarosenberg@uol.com.br
2Department of Genetics and Evolutionary Biology, Institute of Biosciences,
University of São Paulo, Rua do Matão, 277, 05422-970, São Paulo, Brazil
Full list of author information is available at the end of the article
© 2012 Silva et al.; licensee BioMed Central Lt
Commons Attribution License (http://creativec
reproduction in any medium, provided the orconsiderable longer half-life than the wild-type protein,
resulting in accumulation of the mutant protein, at least
in transfected or neoplastic cells [8].
It is known that different mutant p53 proteins may
have diverse functional and biological effects, which
could partially explain the heterogeneity reported be-
tween Li-Fraumeni families [9]. Not only the type of
TP53 mutation determines the tumor spectrum and se-
verity of phenotype, but other germline genetic factors
such as polymorphisms for TP53 and MDM2 [10] and
telomere length [11,12] are assumed to modulate the
cancer phenotype. It has been more recently observed
that individuals carrying TP53 mutations show a ~3-fold
increase in DNA copy number variation (CNV) com-
pared to controls, suggesting that CNVs make an addi-
tive contribution to cancer risk [13].
In Brazil, the Li-Fraumeni syndrome also occurs as a
frequent cancer predisposition alteration due to ad. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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that has been identified in families matching LFS defini-
tions [14,15]. The frequency of p.R337H in the popula-
tion of Southern Brazil is about 1:280 individuals, about
300 times higher than any other single germline TP53
mutation [16]. Analysis of 28 polymorphic markers
showed p.R337H to have arisen from a founder mutation
that has been spreading in the Brazilian population since
the XVIII century [17,18]. This mildly pathogenic muta-
tion shows a penetrance for cancer of less than 20% byTable 1 Clinical data of the patients and characteristics of the
ID Classification Gender TP53mutation Effect p53 protein
functi
Y1T0 Chompret F R213Q
CGA>CAA
Missense DNA bin
Y33T0 LFL Birch F V173M
GTG>ATG
Missense DNA bin
Y53T0 Eeles1 F G245S
GGC>AGC
Missense DNA bin
Y57T0 Eeles1 F G244D
GGC>GAC
Missense DNA bin
Y65T0 Chompret F V197M GTG
>ATG
Missense DNA bin








Y97T1 LFS F IVS8+1G>A Splice DNA bin
Y103T2 LFL/
Chompret
F H214Q Missense DNA bin
Y12T1 LFS F R337H
CGC>CAC
Missense Tetramer
Y15T0 Chompret F R337H
CGC>CAC
Missense Tetramer
Y27T0 LFL Birch F R337H
CGC>CAC
Missense Tetramer
Y49T1 Eeles 1 M R337H
CGC>CAC
Missense Tetramer
Y99T0 Chompret F R337H
CGC>CAC
Missense Tetramer
Y100T0 LFS F R337H
CGC>CAC
Missense Tetramer
Y106T0 Chompret F R337H
CGC>CAC
Missense Tetramer
Y107T0 LFS M R337H
CGC>CAC
Missense Tetramer
Y127T0 Chompret M R337H
CGC>CAC
Missense Tetramer
Y131T0 LFS F R337H
CGC>CAC
Missense Tetramer
Y144T0 Chompret F R337H
CGC>CAC
Missense Tetramer
Y154T0 Chompret F R337H
CGC>CAC
Missense Tetramerage 30, compared to about 50% in classic LFS [18]: this
provides more opportunity for transmitting the mutation
to the next generations, which explains, at least in part,
the maintenance in the Brazilian population.
Structural and functional studies have demonstrated
that the p.R337H protein displays a pH-dependence,
rendering the protein inactive only under conditions of
increased intracellular pH, and the majority of the time
behaves normally, which could explain its lower overall




ding Hydathiform mole (23), Ampulla of Vater (41)
ding Soft tissue sarcoma (23), Breast (43)
ding Bilateral breast (36), Gall bladder (?)
ding Breast (40), Colorectal (?)
ding Colorectal (45), Lung (51), Soft tissue sarcoma (51)
ding Adrenal carcinoma (1)




isation Soft tissue sarcoma (58), Breast (59), Thyroid (61), Soft tissue
sarcoma (62)






isation Adrenal carcinoma (2)
isation Adrenal carcinoma (3)
isation Leg synovial sarcoma (32)
isation Breast (29)
isation Breast (48)
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onset of cancer manifestation linked to various germline
TP53 mutations not only result from the TP53 muta-
tions themselves, but also from their interaction with
other genetic variants, of which CNVs are now becom-
ing recognized as a significant contributant (reviewed in
[20]). Based on the foregoing considerations we hypothesize
that different types of TP53 mutations exhibit different
CNV profiles reflecting the genotype- phenotype correl-
ation and also possibly playing a role in the anticipation
observed in LFS families.
Methods
Patients
The patients were seen in the Department of Oncoge-
netics in the A. C. Camargo Hospital, São Paulo, Brazil.
Research protocol approval was provided by the ethics
committee of the institution, and informed consent
obtained from all subjects and their families. The cohort
comprised 21 probands with TP53 germline mutations
[14]. The characteristics of the mutations, cancer type,
age at onset and clinical classification of the patients are
described in Table 1.
Controls
The CNV control data used in this study was obtained
from a previously reported group of 100 random indivi-
duals from the urban area of São Paulo, Brazil [21].
Array-CGH
We performed oligonucleotide microarray-based CGH
(array-CGH) using a 4 × 180 K whole-genome platform
(design 22060, Agilent Technologies, Santa Clara, USA),
which has an average spacing of 18 Kb between probes.
Briefly, samples were labeled with Cy3- and Cy5-dCTPs
by random priming; purification, hybridization, and wash-
ing were carried out as recommended by the manufac-
turer. Scanned images of the arrays were processed and
analyzed using Feature Extraction software and Genomic
Workbench software (both from Agilent Technologies),
with the statistical algorithm ADM-2, and a sensitivity
threshold of 6.7. We applied a′loop design′ in our hybridi-
zations as previously described [22], resulting in two
reverse labeling hybridizations per sample. We considered
a gain or loss in copy number when the log2 ratio of the
Cy3/Cy5 intensities of a given genomic segment was
>0.5 or <−0.8, respectively. Alterations had to encompass at
least three consecutive probes to be called by the software,
and those not detected in both dye-swap experiments of
the same sample were excluded from the analysis.
Analysis
The detected copy number variations were com-
pared to CNVs reported in the Database of GenomicVariants (DGV; http://projects.tcag.ca/variation/; freeze
December, 2011). We classified the CNVs into ″rare″
and ″common″, considering as ″rare″ those CNVs where
the imbalances encompassed coding sequences which were
never or only once reported in DGV. Mann–Whitney and
Fisher-exact tests were used to evaluate CNVs regarding
proportions of total and rare CNVs, frequency of deletions
and duplications and size of the variation.
The frequencies were then calculated for each rare
variant in the total population described in the DGV
studies. For estimating the total population in DGV,
BAC array publications have been excluded because they
are known to overestimate the CNV boundaries; the
remaining 22 studies comprised a total of 8058 indivi-
duals investigated. The frequencies of these rare variants
were than cross-checked with a study comprising 8148
controls [23], which is not documented in DGV but is
registered in dbVar (www.ncbi.nlm.nih.gov/dbvar).
Results
The CNV data of this study are summarized in Table 2;
a full description of the CNVs identified in the patients
can be found in Additional file 1. The overall frequency
of CNVs per genome did not differ either between
patients and controls or between p.R33H and DBD
mutants (Mann–Whitney test). No significant differ-
ences were detected between the groups regarding CNV
size or frequency of deletions and duplications.
However, with regards to rarity, we found 13 rare
CNVs among all LFS patients, including 9 deletions and
4 duplications. Additional file 2 describes the rare CNVs,
the studies in which they have been observed and their
corresponding frequencies in the combined individuals
of DGV and dbVar. The calculated frequencies of these
rare variants in normal populations as estimated based
both on DGV and dbVar were < 0.1%, a value much in-
ferior to the 1% threshold often associated with
polimorphisms.
In comparison to our control group,TP53 mutated indi-
viduals (p.R337H and DBD) did not exhibit differences in
the total number of CNVs/genome (Figure 1A). However,
we did find a highly significant increase in the rare/
common CNV ratio in the LFS patients carrying muta-
tions in the TP53 DBD when compared to both controls
(p=0.0002) and to patients carrying the p.R337H mutation
(p=0.0156; Fisher-exact test) (Figure 1B). Interestingly, no
significant difference was found between controls and
p.R337H patients.
Discussion
The vast majority of TP53 mutations lies within the
DNA binding domain and target critical sites that either
make contact with DNA or are required to maintain ap-
propriate p53 protein conformation. Such alterations
Table 2 Copy number variation data in controls and LFS/LFL patients classified according to TP53 mutation type
Controls p.R337H carriers DBD mutation carriers
Number of individuals 100 12 9
Number of CNVs 702 92 66
Common 679 89 56
Rare 23 3 10
Average number of all CNVs per diploid genome 7.0±3.1 7.7±2.2 7.3±2.5
Average number of rare CNVs per diploid genome 0.2±0.4 0.2±0.6 1.1±1.3a
Proportion of rare/common CNVs 0.034 0.034b 0.179c
a. difference between controls and DBD mutation carriers (p=0.0026**).
b. difference between p.R337H and DBD mutation carriers (p=0.0156*).
c. difference between controls and DBD mutation carriers (p=0.0002***).
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suppressive activity, with great impact on genomic stabil-
ity and apoptosis [24-26]. In contrast, the p.R337H muta-
tion, which affects a residue of the oligomerization
domain of the p53 protein, has a markedly less severeFigure 1 Distribution of CNVs according to TP53 mutation
status. The graphs show no differences in the frequency of total
CNVs but an increased frequency of rare CNVs in DBD mutation
carriers. (A) Frequency of total CNVs in LFS patients and controls;
(B) Rare/common CNV ratio in LFS patients and controls. White bar
represents the control individuals, grey bar represents p.R337H
mutated carriers and dark black bar the TP53 DBD mutated carriers.
Fisher-exact test; *p=0.0156 and ***p=0.0002.impact on tumor predisposition, which correlates with its
remaining p53 activity [19,27].
Shlien et al. [13] reported a ~3-fold increase in the fre-
quency of CNVs in TP53 germline mutation carriers
compared to normal individuals, and proposed that this
increase might result from enhanced genome instability
in the presence of TP53 mutations. In our study, we
found no difference between the total number of germ-
line CNVs present in LFS patients and controls; how-
ever, we noted a highly significant increase (>5 fold) in
the rare CNVs in TP53 DBD mutation carriers as com-
pared both to controls and to p.R337H carriers. A differ-
ence between Shlien et al. [13] data and ours refers to
the controls samples: in their work data previously
assembled in other studies were used to establish a base-
line CNV control frequency, whereas our control and
patient samples have been investigated in parallel in the
same laboratory. We should also point out that the stud-
ies were carried out using different microarray technolo-
gies, namely array-CGH and SNP platforms. In fact, a
large study comparing different platforms found that dif-
ferent analytic tools typically yield CNV calls with <50%
concordance, overall regarding smaller CNVs [28].
An increase of only rare germline CNVs in the DBD
TP53 carriers, rather than an overall increase in CNVs,
suggests that a selective mechanism would be involved
in this event. Under the assumption that pathogenic var-
iants would only remain in the population at low fre-
quency, the selection against new pathogenic CNVs (in
the context of studies on schizophrenia and autism, re-
spectively) is extremely high [29,30]. The finding of an
increased proportion of rare CNVs, potentially patho-
genic, among TP53 DBD mutants may be the result of
an inefficient selection against new CNVs (deficient
apoptosis). This hypothesis could be tested by determin-
ing the pattern of inheritance of the CNVs [13], but un-
fortunately parents were not available for investigation.
Anticipation, characterized by an increase of pene-
trance and earlier age of onset over subsequent genera-
tions, has been well documented for LFS [5,6]. An
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disposition in LFS provides a logical explanation for an-
ticipation. How CNVs and other genetic modifiers
interact and modulate TP53 tumor suppressor activities
remains to be determined. Elucidating these mechanisms
may hold the key to defining evidence-based strategies
for diagnosis, counseling, follow-up and therapeutic care
based on a detailed understanding of the nature of com-
bined risk between TP53 and other variants, including
CNVs.
Conclusions
In this work we show a highly significant increase of rare
CNVs in patients with mutations in the TP53 DNA
binding domain site (DBD) relative both to controls and
to carriers of the mild TP53 Brazilian variant. An accu-
mulation of rare CNVs over generations in the presence
of penetrant TP53 mutation provides a plausible explan-
ation for anticipation in LFS: in contrast, lack of this in-
crease in rare CNVs combined with a longer lifespan
and likelihood of reproduction probably contributes to
the frequency of the p.R337H mutation being ~300 xs
larger than reported for any other TP53 mutation.
Availability of supporting data
The data set supporting the results of this article is
included within the article and its additional files.
Additional files
Additional file 1: Results of Array-CGH. Full CNV data of LFS/LFL
patients, chromosome coordinates given according to Hg18 (NCBI Build
36.1/hg18; http://genome.ucsc.edu).
Additional file 2: Frequency of the rare CNVs detected in the TP53
mutated individuals.
Abbreviations
LFS: Li-Fraumeni syndrome; LFL: Li-Fraumeni like syndrome; CNV: Copy
number variation; DBD: DNA binding domain.
Competing interests
The authors declare that they have no competing interests.
Authors' contributions
AGS carried out the molecular genetic studies. AGS and PLP wrote the
manuscript. ACVK and CR participated in the design and coordination of the
study and helped writing the manuscript. MIWA recruited and selected the
patients. All authors read and approved the final manuscript.
Acknowledgements
We thank all patients for their participation to this study. We also thank the
Brazilian National Institute of Science and Technology in Oncogenomics and
FAPESP for financial support. Amanda G. Silva and Maria Isabel W Achatz are
the first 2 authors that should be regarded as joint First Authors.
Author details
1International Center for Research and Training, A. C. Camargo Hospital, Rua
Taguá, 440, 01508-010, São Paulo, Brazil. 2Department of Genetics and
Evolutionary Biology, Institute of Biosciences, University of São Paulo, Rua do
Matão, 277, 05422-970, São Paulo, Brazil.Received: 11 May 2012 Accepted: 11 December 2012
Published: 21 December 2012References
1. Li FP, Fraumeni JF, Mulvihill JJ, Blattner WA, Dreyfus MG, Tucker MA,
Miller RW: A cancer family syndrome in twenty-four kindreds. Cancer Res
1988, 48(18):5358–5362.
2. Birch JM, Alston RD, McNally RJ, Evans DG, Kelsey AM, Harris M, Eden OB,
Varley JM: Relative frequency and morphology of cancers in carriers of
germline TP53 mutations. Oncogene 2001, 20(34):4621–4628.
3. Malkin D, Li FP, Strong LC, Fraumeni JF, Nelson CE, Kim DH, Kassel J,
Gryka MA, Bischoff FZ, Tainsky MA: Germ line p53 mutations in a familial
syndrome of breast cancer, sarcomas, and other neoplasms. Science
1990, 250(4985):1233–1238.
4. Eeles RA: Germline mutations in the TP53 gene. Cancer Surv 1995,
25:101–124.
5. Trkova M, Hladikova M, Kasal P, Goetz P, Sedlacek Z: Is there anticipation
in the age at onset of cancer in families with Li-Fraumeni syndrome?
J Hum Genet 2002, 47(8):381–386.
6. Brown BW, Costello TJ, Hwang SJ, Strong LC: Generation or birth cohort
effect on cancer risk in Li-Fraumeni syndrome. Hum Genet 2005,
118(3–4):489–498.
7. Levine AJ, Momand J, Finlay CA: The p53 tumour suppressor gene. Nature
1991, 351(6326):453–456.
8. Andersen TI, Holm R, Nesland JM, Heimdal KR, Ottestad L, Børresen AL:
Prognostic significance of TP53 alterations in breast carcinoma. Br J
Cancer 1993, 68(3):540–548.
9. Petitjean A, Achatz MI, Borresen-Dale AL, Hainaut P, Olivier M: TP53
mutations in human cancers: functional selection and impact on cancer
prognosis and outcomes. Oncogene 2007, 26(15):2157–2165.
10. Marcel V, Palmero EI, Falagan-Lotsch P, Martel-Planche G, Ashton-Prolla P,
Olivier M, Brentani RR, Hainaut P, Achatz MI: TP53 PIN3 and MDM2 SNP309
polymorphisms as genetic modifiers in the Li-Fraumeni syndrome:
impact on age at first diagnosis. J Med Genet 2009, 46(11):766–772.
11. Tabori U, Nanda S, Druker H, Lees J, Malkin D: Younger age of cancer
initiation is associated with shorter telomere length in Li-Fraumeni
syndrome. Cancer Res 2007, 67(4):1415–1418.
12. Trkova M, Prochazkova K, Krutilkova V, Sumerauer D, Sedlacek Z: Telomere
length in peripheral blood cells of germline TP53 mutation carriers is
shorter than that of normal individuals of corresponding age. Cancer
2007, 110(3):694–702.
13. Shlien A, Tabori U, Marshall CR, Pienkowska M, Feuk L, Novokmet A,
Nanda S, Druker H, Scherer SW, Malkin D: Excessive genomic DNA copy
number variation in the Li-Fraumeni cancer predisposition syndrome.
Proc Natl Acad Sci USA 2008, 105(32):11264–11269.
14. Achatz MI, Olivier M, Le Calvez F, Martel-Planche G, Lopes A, Rossi BM,
Ashton-Prolla P, Giugliani R, Palmero EI, Vargas FR, et al: The TP53 mutation,
R337H, is associated with Li-Fraumeni and Li-Fraumeni-like syndromes in
Brazilian families. Cancer Lett 2007, 245(1–2):96–102.
15. Palmero EI, Schüler-Faccini L, Caleffi M, Achatz MI, Olivier M, Martel-Planche G,
Marcel V, Aguiar E, Giacomazzi J, Ewald IP, et al: Detection of R337H, a
germline TP53 mutation predisposing to multiple cancers, in
asymptomatic women participating in a breast cancer screening program
in Southern Brazil. Cancer Lett 2008, 261(1):21–25.
16. Achatz MI, Hainaut P, Ashton-Prolla P: Highly prevalent TP53 mutation
predisposing to many cancers in the Brazilian population: a case for
newborn screening? Lancet Oncol 2009, 10(9):920–925.
17. Pinto EM, Billerbeck AE, Villares MC, Domenice S, Mendonça BB,
Latronico AC: Founder effect for the highly prevalent R337H mutation
of tumor suppressor p53 in Brazilian patients with adrenocortical
tumors. Arq Bras Endocrinol Metabol 2004, 48(5):647–650.
18. Garritano S, Gemignani F, Palmero EI, Olivier M, Martel-Planche G,
Le Calvez-Kelm F, Brugiéres L, Vargas FR, Brentani RR, Ashton-Prolla P, et al:
Detailed haplotype analysis at the TP53 locus in p.R337H mutation
carriers in the population of Southern Brazil: evidence for a founder
effect. Hum Mutat 2010, 31(2):143–150.
19. DiGiammarino EL, Lee AS, Cadwell C, Zhang W, Bothner B, Ribeiro RC,
Zambetti G, Kriwacki RW: A novel mechanism of tumorigenesis involving
pH-dependent destabilization of a mutant p53 tetramer. Nat Struct Biol
2002, 9(1):12–16.
Silva et al. Orphanet Journal of Rare Diseases 2012, 7:101 Page 6 of 6
http://www.ojrd.com/content/7/1/10120. Kuiper RP, Ligtenberg MJ, Hoogerbrugge N, Geurts Van Kessel A: Germline
copy number variation and cancer risk. Curr Opin Genet Dev 2010,
20(3):282–289.
21. Krepischi AC, Achatz MI, Santos EM, Costa SS, Lisboa BC, Brentani H,
Santos TM, Goncalves A, Nobrega AF, Pearson PL, et al: Germline DNA
copy number variation in familial and early-onset breast cancer.
Breast Cancer Res 2012, 14(1):R24.
22. Allemeersch J, Van Vooren S, Hannes F, De Moor B, Vermeesch JR,
Moreau Y: An experimental loop design for the detection of
constitutional chromosomal aberrations by array CGH. BMC Bioinformatics
2009, 10:380.
23. Xu H, Poh WT, Sim X, Ong RT, Suo C, Tay WT, Khor CC, Seielstad M, Liu J,
Aung T, et al: SgD-CNV, a database for common and rare copy number
variants in three Asian populations. Hum Mutat 2011, 32(12):1341–1349.
24. Camplejohn RS, Perry P, Hodgson SV, Turner G, Williams A, Upton C,
MacGeoch C, Mohammed S, Barnes DM: A possible screening test for
inherited p53-related defects based on the apoptotic response of
peripheral blood lymphocytes to DNA damage. Br J Cancer 1995,
72(3):654–662.
25. Goi K, Takagi M, Iwata S, Delia D, Asada M, Donghi R, Tsunematsu Y,
Nakazawa S, Yamamoto H, Yokota J, et al: DNA damage-associated
dysregulation of the cell cycle and apoptosis control in cells with
germ-line p53 mutation. Cancer Res 1997, 57(10):1895–1902.
26. Malkin D: Li-fraumeni syndrome. Genes Cancer 2011, 2(4):475–484.
27. Zambetti GP: The p53 mutation ″gradient effect″ and its clinical
implications. J Cell Physiol 2007, 213(2):370–373.
28. Pinto D, Darvishi K, Shi X, Rajan D, Rigler D, Fitzgerald T, Lionel AC,
Thiruvahindrapuram B, Macdonald JR, Mills R, et al: Comprehensive
assessment of array-based platforms and calling algorithms for
detection of copy number variants. Nat Biotechnol 2011, 29(6):512–520.
29. Rees E, Moskvina V, Owen MJ, O0Donovan MC, Kirov G: De novo rates and
selection of schizophrenia-associated copy number variants. Biol
Psychiatry 2011, 70(12):1109–1114.
30. Itsara A, Wu H, Smith JD, Nickerson DA, Romieu I, London SJ, Eichler EE: De
novo rates and selection of large copy number variation. Genome Res
2010, 20(11):1469–1481.
doi:10.1186/1750-1172-7-101
Cite this article as: Silva et al.: Number of rare germline CNVs and TP53
mutation types. Orphanet Journal of Rare Diseases 2012 7:101.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
